S&P rates U.S. Renal Care loans B+

Standard & Poor's said it assigned a B corporate credit rating to U.S. Renal Care Inc. and a B+ senior secured debt rating to the company's proposed $30 million revolving credit facility maturing in 2015 and $125 million term loan facility maturing in 2016 with a recovery rating of 2.

The outlook is stable.

"The speculative-grade ratings reflect USRC's dependence upon a single disease state treatment; challenges associated with the integration of Dialysis Corp. of America; exposure to adverse changes in payor mix and reimbursement; and its relatively small size with very limited geographic diversity," S&P analyst Jack Harcourt said in a statement.

The company's vulnerable business risk profile overwhelmingly reflects the its dependence upon a single disease state, as well as its relatively small size and limited geographic diversity, the agency said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.